(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 83.8MM | - |
Gross Profit | 83.5MM | - |
Cost Of Revenue | 260K | -14% |
Operating Income | -4.2MM | -91% |
Operating Expenses | 87.7MM | - |
Net Income | -48.6MM | -25% |
R&D | 66.7MM | +30% |
G&A | 21.2MM | +12% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
There's been a notable change in appetite for Agenus Inc. ( NASDAQ:AGEN ) shares in the week since its yearly report...
Agenus Inc. (NASDAQ:AGEN) Q4 2023 Earnings Call Transcript March 14, 2024 Agenus Inc. misses on earnings expectations. Reported EPS is $-0.13 EPS, expectations were $-0.053. AGEN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. My name is Audra, […]
The latest analyst coverage could presage a bad day for Agenus Inc. ( NASDAQ:AGEN ), with the analysts making...
AGEN earnings call for the period ending December 31, 2023.
Fast Track Designation for BOT/BAL in Colorectal Cancer and $25 Million Milestone Payment Highlight Progress
LEXINGTON, Mass., March 14, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.
LEXINGTON, Mass., March 06, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the first preclinical data from BMS-986442 (AGEN1777) will be presented in an oral presentation at the upcoming AACR Meeting, to be held April 5 – 10, 2024 in San Diego, CA.
LEXINGTON, Mass., March 05, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus’ Board of Directors granted inducement awards to Nils Eckardt, Kent Barnes, and Brian Greenblatt, in connection with their appointments as Chief Medical Affairs Officer, Head of Marketing and Sales, and Vice President Commercial Operations and Business Analytics, respectively.
LEXINGTON, Mass., February 29, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Company will release its fourth quarter and year end 2023 financial results before the market opens on Thursday, March 14, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.
LEXINGTON, Mass., February 26, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Leerink Global Biopharma Conference on March 11th - 13th in Miami Beach, Florida. The fireside chat will take place at 2:30 p.m. ET on March 11th.